Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Therapeutic App for Hypertension Up for PAFSC Review on March 9
A key health ministry advisory organ will discuss whether to recommend approval for a digital therapeutic app for hypertension treatment developed by Tokyo-based health tech CureApp at its meeting on March 9. The app is designed to encourage changes in…
To read the full story
Related Article
- Teijin to Copromote CureApp’s Hypertension Therapy App
April 24, 2024
- Hypertension Therapy App Might Reduce Use of Antihypertensives: CureApp
April 10, 2024
- CureApp’s Hypertension Therapeutic App Shows Effects in Clinical Setting
September 27, 2023
- CureApp’s Hypertension Therapeutic App Rolls Out with Insurance Coverage
September 2, 2022
- Chuikyo OKs Insurance Coverage for CureApp’s Hypertension Therapeutic App
August 5, 2022
- CureApp Wins Japan Nod for Hypertension Therapeutic App, Eyes 2022 Rollout
April 28, 2022
- Therapeutic App for Hypertension Now in Line for April Approval
March 10, 2022
- CureApp Files Therapeutic App for Hypertension in Japan, Eyes Launch in 2022
September 6, 2021
- CureApp Hypertension Therapeutic App Hits PIII Goal, 2021 Submission Eyed
March 17, 2021
- Japan’s 1st Therapeutic App Now Available: CureApp
December 2, 2020
- CureApp to File Hypertension Treatment App as Early as 2021, PIII Trial Now Underway
February 3, 2020
REGULATORY
- Japan Has Limited Drug Pricing Cards to Play on MFN, Should Expand CEA: MOF Official
October 5, 2026
- RMPs to Become Statutory Requirement under PMD Act in May 2027
October 5, 2026
- Japan Panel Calls for Better Infrastructure to Expand RLT Access
October 5, 2026
- Drug Discovery Fund Cleared to Provide Funding to Startups
October 5, 2026
- MHLW Simplifies Repatha Optimal Use Guidelines
October 5, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…